GlassScriptPhysician profile
Mit Kishorchandra Desai
NPI 1174783310
$1,581.90
in general payments reported to CMS, 2019-2025
24 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $47.64 · 2021: $111 · 2022: $181 · 2023: $256 · 2024: $374 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $247.38 | 2020-2025 | Breztri, Lokelma |
| Abbvie INC. | $177.89 | 2021-2025 | Teflaro |
| Novartis Pharmaceuticals Corporation | $144.43 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $141.82 | 2019-2024 | Xarelto |
| Avanir Pharmaceuticals, INC. | $139.84 | 2019 | |
| Pfizer INC. | $133.74 | 2021-2024 | |
| Inari Medical, INC. | $120.84 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Otsuka America Pharmaceutical, INC. | $108.76 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $79.25 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.09 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.07 | 2025 | Xifaxan |
| Abiomed | $23.45 | 2025 | |
| Stryker Corporation | $22.86 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Mylan Specialty L.P. | $22.18 | 2020 | |
| Recor Medical INC | $20.81 | 2024 | Paradise Renal Denervation System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.57 | 2023 | Mitraclip |
| Atricure, INC. | $18.77 | 2023 | |
| Smith+Nephew, INC. | $18.37 | 2025 | Collagenase Santyl |
| Boston Scientific Corporation | $17.75 | 2024 | Watchman Flx |
| Inspire Medical Systems, INC. | $17.16 | 2025 | Inspire |
| Bioxcel Therapeutics, INC. | $15.85 | 2023 | Igalmi |
| Amarin Pharma, INC. | $15.27 | 2021 | |
| Gilead Sciences, INC. | $14.74 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mit Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.